Prakt. Lékáren. 2019; 15(1e): 36-40 [Interní Med. 2018; 20(4): 167-170]

Latest developments in the management of resistant hypertension

Renata Cífková
Centrum kardiovaskulární prevence 1. LF UK a TN, Praha

Hypertension resistant to treatment is currently defined as a situation when the recommended treatment strategy fails to lower office blood
pressure to values < 140/90 mmHg, and inadequate control of blood pressure is confirmed by ambulatory blood pressure monitoring or home
blood pressure measurement. The recommended treatment strategy should include treatment with optimal or best-tolerated doses of three or more drugs that should include a diuretic and, typically, an ACE inhibitor or angiotensin receptor blocker and a calcium-channel blocker. The
estimated prevalence using the above definition is likely to be < 10% of treated patients. Pseudoresistant hypertension and secondary causes
of hypertension should be excluded. The recommended treatment strategy should include treatment with optimal or best-tolerated doses
of three or more drugs that should include a diuretic and, typically, an ACE inhibitor or angiotensin receptor blocker and a calcium-channel
blocker. The fourth-line treatment should include spironolactone (up to 50 mg a day). Fixed combinations are preferred.

Keywords: pseudoresistant hypertension, ACE inhibitors, angiotensin receptor blockers, secondary hypertension, 24h ambulatory BP monitoring,home BP measurement

Published: March 15, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Cífková R. Latest developments in the management of resistant hypertension. Praktické lékárenství. 2019;15(E-verze 1/19):36-40.
Download citation

References

  1. Williams B, Mancia G, et al., 2018 ESC-ESH Guidelines for the Management of Arterial Hypertension,Eur Heart J 2018 Aug 25. doi: 10.1093/eurheartj/ehy339. [Epub ahead of print] a J Hypertens 2018 v tisku. Go to original source... Go to PubMed...
  2. Gupta P, Patel P, Horne R, Buchanan H, Williams B, Tomaszewski M. How to Screen for Non-Adherence to Antihypertensive Therapy. Curr Hypertens Rep 2016; 18: 89. Go to original source... Go to PubMed...
  3. Gupta P, Patel P, Strauch B, Lai FY, Akbarov A, Gulsin GS, Beech A, Maresova V, Topham PS, Stanley A, Thurston H, Smith PR, Horne R, Widimsky J, Keavney B, Heagerty A, Samani NJ, Williams B, Tomaszewski M. Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. Hypertension 2017; 70: 1042-1048. Go to original source... Go to PubMed...
  4. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J 2014; 35: 1245-1254. Go to original source... Go to PubMed...
  5. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009; 54: 475-481. Go to original source... Go to PubMed...
  6. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford 4770 I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ, British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386: 2059-2068. Go to original source... Go to PubMed...
  7. Liu L, Xu B, Ju Y. Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials. Clin Exp Hypertens 2017; 39(3): 257-263. doi: 10.1080/10641963.2016.1246564.Review. Go to original source... Go to PubMed...
  8. Zhao D, Liu H, Dong P, Zhao J. A meta-analysis of add-on use of spironolactone in patients with resistant hypertension. Int J Cardiol 2017; 233: 113-117. Go to original source... Go to PubMed...
  9. Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, Ford I, Cruickshank JK, Caulfield MJ, Padmanabhan S, Mackenzie IS, Salsbury J, Brown MJ, British Hypertension Society programme of Prevention Treatment of Hypertension With Algorithm based Therapy Study Group. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol 2018;Apr 11. pii: S2213-8587(18)30071-8. doi: 10.1016/S2213-8587(18)30071-8. [Epub ahead of print]. Go to original source... Go to PubMed...




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.